Business Context and Reporting Period
The filing is a Form 10-Q for the quarter and nine months ended September 30, 2013. The filing identifies the registrant as Neuralstem, Inc., not Palisade Bio, Inc.; this company-name discrepancy should be verified. Neuralstem was a development-stage biotechnology company focused on human neuronal stem-cell therapies and small-molecule compounds, with operations in the United States and China.
Financial Highlights
| Metric | Three months ended Sept. 30, 2013 | Nine months ended Sept. 30, 2013 |
|---|---|---|
| Revenue | $2,500 | $107,500 |
| Operating expenses | $3.64 million | $9.87 million |
| Operating loss | $3.63 million | $9.76 million |
| Net loss | $6.69 million | $16.53 million |
| Loss per share | $0.09 | $0.23 |
| Net cash used in operating activities | Not separately presented | $8.12 million |
- Cash and cash equivalents were $16.40 million at September 30, 2013, compared with $7.44 million at December 31, 2012.
- Working capital surplus was approximately $12.18 million; stockholders’ equity was $8.27 million.
- Debt consisted primarily of an $8 million term loan issued in March 2013, with approximately $7.65 million recorded net of discount and current portion at September 30, 2013. The loan bears variable interest with an 11% floor, matures in June 2016, and is secured by substantially all assets, including intellectual property.
- Net cash provided by financing activities was $17.51 million, including $7.55 million of net debt proceeds, $5.84 million from warrant exercises, and $4.24 million from an equity offering.
- Reported operating and net profit margins were not meaningful because revenue was negligible and the company incurred substantial losses.
Material Changes Versus Prior Comparable Period
- Third-quarter revenue declined to $2,500 from $170,833, while nine-month revenue declined to $107,500 from $405,208. The prior-year period included revenue from a completed Department of Defense subcontract and higher licensing revenue.
- Third-quarter operating expenses increased 32% to $3.64 million; research and development increased 33% to $1.85 million and general and administrative expense increased 33% to $1.71 million.
- Nine-month operating expenses increased 26% to $9.87 million, reflecting increased clinical-trial and research activity, personnel and professional-service costs, and share-based compensation.
- Nine-month net loss increased to $16.53 million from $7.41 million. The increase was significantly affected by $5.02 million of warrant modification expense, $859,682 of derivative fair-value losses, and $936,471 of interest expense.
- Cash used in operations increased 36% to $8.12 million, while investing cash use increased to $444,721 from $188,318.
- Shares outstanding increased to approximately 76.66 million from 68.19 million at December 31, 2012. The company also had substantial outstanding options and warrants, creating potential dilution.
Guidance, Outlook, Risks, and Unusual Items
- Management estimated monthly operating cash requirements of approximately $1.0 million and stated that available cash, expected income, and expected securities proceeds should fund current activities at least through September 30, 2014, although activities and personnel may need to be reduced.
- The company did not expect to be profitable in the next several years and stated that significant additional capital would be required. A shelf registration for up to $50 million of securities was effective, and an October 25, 2013 at-the-market agreement permitted potential sales of up to $20 million of common stock.
- Clinical plans included continued Phase II dosing of NSI-566 for ALS, anticipated completion of dosing in the second quarter of 2014, and planned Phase I or combined Phase I/II trials for chronic spinal cord injury and ischemic-stroke motor deficits. NSI-189 Phase Ib dosing was complete, with final data expected in the fourth quarter of 2013 and partnering discussions underway.
- There was no revenue from commercial product sales. Product candidates remained subject to clinical, regulatory, manufacturing, reimbursement, and commercialization uncertainties.
- The company’s debt was secured by substantially all assets and was subject to affirmative and restrictive covenants. Failure to refinance or repay debt or comply with covenants could result in acceleration and potential foreclosure.
- Neuralstem was involved in long-running patent litigation with StemCells, Inc.; the court was addressing whether StemCells had standing to pursue infringement claims. The ultimate outcome and timing were unknown.
- The company asserted entitlement to a $250,000 milestone payment from ReNeuron, while ReNeuron disputed that the milestone had been achieved. No revenue had been recognized.
- Significant non-cash or unusual charges included warrant modification expense, derivative fair-value losses, share-based compensation of $2.08 million for the first nine months, and amortization of debt discounts and financing fees.
Important Facts for Investors to Verify
- Registrant identity: confirm whether the requested company should be Neuralstem, Inc. or Palisade Bio, Inc.
- Cash runway assumptions, including the approximately $1.0 million monthly operating cash requirement and expected financing proceeds.
- Debt terms, collateral coverage, covenants, maturity, and repayment requirements beginning after the interest-only period.
- Potential dilution from approximately 19.8 million outstanding warrants, 16.3 million outstanding options, equity offerings, and future ATM or shelf-registration sales.
- Clinical-trial enrollment, safety and efficacy data, regulatory status, and the timing of expected NSI-189 data.
- Status and potential financial impact of the StemCells patent litigation and the disputed ReNeuron milestone.
- Whether management’s stated liquidity outlook remains valid given continuing losses, negligible product revenue, and dependence on external financing.